In vivo imaging of protease activity by Probody therapeutic activation  by Wong, Kenneth R. et al.
lable at ScienceDirect
Biochimie 122 (2016) 62e67Contents lists avaiBiochimie
journal homepage: www.elsevier .com/locate/b iochiResearch paperIn vivo imaging of protease activity by Probody therapeutic activation
Kenneth R. Wong a, Elizabeth Menendez a, Charles S. Craik b, W. Michael Kavanaugh a,
Olga Vasiljeva a, *
a CytomX Therapeutics, Inc., 343 Oyster Point Blvd, South San Francisco, CA 94080, USA
b Department of Pharmaceutical Chemistry, University of California, 600 16th Street, San Francisco, CA 94158, USAa r t i c l e i n f o
Article history:
Received 29 September 2015
Accepted 2 November 2015
Available online 4 November 2015
Keywords:
Protease activity
Monoclonal antibody
In vivo imaging
Tumor targeting* Corresponding author.
E-mail address: olga@cytomx.com (O. Vasiljeva).
http://dx.doi.org/10.1016/j.biochi.2015.11.003
0300-9084/© 2015 The Authors. Published by Elseviera b s t r a c t
Probody™ therapeutics are recombinant, proteolytically-activated antibody prodrugs, engineered to
remain inert until activated locally by tumor-associated proteases. Probody therapeutics exploit the
fundamental dysregulation of extracellular protease activity that exists in tumors relative to healthy
tissue. Leveraging the ability of a Probody therapeutic to bind its target at the site of disease after
proteolytic cleavage, we developed a novel method for proﬁling protease activity in living animals. Using
NIR optical imaging, we demonstrated that a non-labeled anti-EGFR Probody therapeutic can become
activated and compete for binding to tumor cells in vivo with a labeled anti-EGFR monoclonal antibody.
Furthermore, by inhibiting matriptase activity in vivowith a blocking-matriptase antibody, we show that
the ability of the Probody therapeutic to bind EGFR in vivo was dependent on protease activity. These
results demonstrate that in vivo imaging of Probody therapeutic activation can be used for screening and
characterization of protease activity in living animals, and provide a method that avoids some of the
limitations of prior methods. This approach can improve our understanding of the activity of proteases in
disease models and help to develop efﬁcient strategies for cancer diagnosis and treatment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Proteases have long been associated with cancer invasion and
metastasis due to their ability to degrade extracellular matrix
components and their regulation of cleavage, processing, or shed-
ding of cell signaling molecules [1]. The proteolytic tumor micro-
environment is complex, characterized by structurally and
functionally diverse proteases that include the matrix metal-
loproteinases (MMPs), serine proteases, and others [2,3]. The Pro-
body technology leverages the upregulation of the activity of these
proteases in the tumor microenvironment to achieve disease
tissue-speciﬁc therapeutic activity. Probody therapeutics contain a
masking peptide fused to the N-terminus of the light chain of the
antibody through a protease-cleavable linker peptide (Fig. 1). In the
intact form, the mask physically prevents the Probody therapeutic
from binding to the target antigen in healthy tissues; however, in
the diseased environment, the linker is cleaved and the masking
peptide is released, resulting in a fully active antibody capable of
binding to its target antigen. As such, the proteolytically cleavableB.V. This is an open access article ulinker, which contains a substrate sequence recognized by one or
more proteases, can serve to proﬁle the proteolytic environment of
the tumor microenvironment.
In order to develop substrates that are efﬁciently cleaved at sites
of disease, a better understanding of the regulation of protease
activity in tumors is needed. However, dissecting how proteases
carry out their biological functions in vivo has been challenging,
because their activities are regulated by redundant mechanisms,
including regulation of biosynthesis at the transcription and
translation levels, localization, activation of zymogens and binding
of endogenous inhibitors and cofactors. Several methods have been
developed to identify the presence of proteases and their activity,
including activity-based probes [4,5], active site antibodies [6e8]
and proteomics-based approaches [9]. Here we present a new
approach for detection of in vivo protease activity, through in vivo
optical imaging using Probody technology. Optical imaging has
become a useful approach in biomedical sciences because it is a fast,
sensitive, and cost-effective method to track and characterize
expression of a target, detect enzyme activity and monitor cancer
progression or regression and response to therapies in living ani-
mals. Leveraging the ability of a Probody therapeutic to bind to a
target at the site of disease in a protease-dependent manner, wender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Structure and design of Probody therapeutics. (A) A Probody therapeutic is a monoclonal antibody that contains a light chain extension consisting of a masking peptide (cyan)
that blocks the antigen-binding site (yellow), and a protease-speciﬁc substrate-containing linker (orange). (B) In the absence of active protease, the Probody therapeutic is
functionally masked and cannot effectively interact with target. (C) In the presence of the targeted active protease (green), the linker is cleaved, the masking peptide disassociates,
and the Probody therapeutic becomes competent to bind to its target.
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of protease activity in vivo.
2. Methods
2.1. Probody therapeutic expression, puriﬁcation and labeling
Probody therapeutics were generated as previously described
[10]. In brief, Probody therapeutics were expressed in a modiﬁed
pcDNA3.1 mammalian expression vector (Life Technologies) and
produced in CHO-S cells (Life Technologies). Probody therapeutics
were afﬁnity-puriﬁed with MabSelect SuRe protein A columns (GE
Healthcare) coupled to an AKTA FPLC (GE Healthcare). The purity of
puriﬁed Probody therapeutics was analyzed by SDS-PAGE, and their
homogeneity was analyzed by size exclusion chromatography with
a Superdex 200, 10/300 GL column (GE Healthcare).
Antibodies and Probody therapeutics were labeled with a near-
infrared ﬂuorescent Alexa Fluor® 750 dye (ThermoFisher Scientiﬁc,
A20111) by incubation for 1 h at room temperature. The reaction
was stopped with 1 M TriseHCl buffer, pH 8.5 and labeled antibody
and Probody therapeutics were separated from free dye using Zeba
desalting columns (Life Technologies, 87768). Degree of labeling
(DOL) was determined with NanoDrop spectrophotometer. Anti-
bodies and Probody therapeutics with DOL of 2e3 were used in the
imaging studies.
2.2. H292 xenograft model
All animal experiments were approved by our Institutional
Animal Care Committee (IACUC). Mice were maintained with free
access to standard chow and water. NCI-H292 human lung cancer
cells were obtained from the American Type Culture Collection
(ATCC). They were cultured in RPMI medium supplemented with
10% (v/v) fetal bovine serum (FBS). The cells were maintained in a
humidiﬁed atmosphere of 5% CO2 at 37 C. For H292 xenograft
studies, 7- to 9-week-old female athymic nu/nu (Charles River
Laboratories) mice were inoculated subcutaneously in the righthind ﬂank with 5  106 NCI-H292 cells (ATCC) suspended 1:1 (v/v)
with Matrigel in serum-free medium. Clinical observations, body
weights, and digital caliper tumor volume measurements were
made two times weekly once tumors became measureable. Tumor
volumes were calculated with the formula (ab2)/2, where a is the
longer and b is the smaller of two perpendicular diameters.
2.3. In vivo imaging of protease activity using Probody therapeutics
and competition binding to EGFR
H292 xenograft tumor-bearing mice with tumor volumes of
250e500 mm3 were evenly distributed by tumor size into 3 groups
with n ¼ 3 per group. The animals were then pretreated by an
intraperitoneal injection of 10 mg/kg of the anti-EGFR Probody
therapeutic. Control group mice were intraperitoneally injected
with PBS or a 10 mg/kg of cetuximab, an anti-EGFR monoclonal
antibody. Forty-eight hours after pretreatment all mice were
injected intraperitoneally with 10 mg/kg of AlexaFluor 750
(AF750)-conjugated cetuximab (Cetuximab-AF750).
Spectral ﬂuorescence images of the mice were obtained with an
IVIS Spectrum/CT imaging system (Caliper Life Sciences, PE) at 48 h
and 72 h after Cetuximab-AF750 injection using excitation and
emission wavelengths of 745 nm and 800 nm, respectively. During
the procedure, the mice were kept under gaseous anesthesia (5%
isoﬂuorane) at 37 C.
2.4. Protease inhibitor A11 blocking studies with Pb-Tx in vivo
imaging
H292 xenograft tumor-bearing mice with tumor volumes of
350e750 mm3 were evenly distributed by tumor size into two
groups with n¼ 3 per group. The animals were then pre-treated by
an intraperitoneal injection of 15 mg/kg of A11, a human recom-
binant antibody that recognizes the active form of matriptase over
the zymogen form and is a speciﬁc inhibitor of its activity. The
control group mice were intraperitoneally injected with 15 mg/kg
of monoclonal anti-CD20 antibody rituximab. Twenty-four hours
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10 mg/kg of AlexaFluor 750 (AF750)-conjugated Probody thera-
peutic, (Pb-Tx-AF750). Spectral ﬂuorescence images of the mice
were obtained at 24 h and 72 h after Pb-Tx-AF750 injection.
2.5. In vivo imaging data analysis
Bright-ﬁeld photographs were obtained with each image. The
merged bright-ﬁeld photographs and ﬂuorescence images were
generated using Living Image software 4.1.3 (Caliper Life Sciences).
Tumor-associated ﬂuorescence intensities were quantiﬁed in the
region of interest (ROI). Identical illumination settings (lamp
voltage, ﬁlters, f/stop, ﬁeld of views, binning) were used for
acquiring all images, and the ﬂuorescence emissionwithin each ROI
was determined as the average photons per second per centimeter
square per steradian (p/s/cm2/sr) in the quantitative analysis.
Fluorescent intensities detected in tumors were further normalized
with their corresponding background signals (tumor-to-back-
ground ratio, TBR). Data are presented as the mean ± SEM of three
individual mice.
2.6. Statistical analysis
All mice used for the in vivo imaging studies were included in
the analysis. Mean NIR ﬂuorescence signals as represented by tu-
mor to background ratios (TBR) of average radiant efﬁciency with
SEMwere plotted. 48 h and 72 h TBR values were calculated for one
mouse in the A11/Pb-Tx-AF750 group by interpolation of linear
regression analysis based on 0 h, 24 h and 96 h TBR data. A two-
tailed Student's t test was performed with Microsoft Excel to
assess the statistical signiﬁcance of TBR differences between
treated and control groups. P values of 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. In vivo imaging of Probody therapeutic by use of competitive
target binding
A Probody therapeutic is a fully recombinant biotherapeutic
comprised of a monoclonal antibody whose binding to target an-
tigen is blocked by an extension of the NH2-terminus of the light
chain, called amasking peptide (Fig.1a and b). Themasking peptide
is connected to the light chain by a linker containing a substrate for
one or more proteases. Upon cleavage of the substrate-linker by
tumor-associated proteases, themask is removed, and the activated
Probody therapeutic binds its target, resulting in tumor-localized
activity (Fig. 1c). We previously described a novel anti-epidermal
growth factor receptor (EGFR)edirected Probody therapeutic (Pb-
Tx) that is efﬁcacious in mouse xenograft models and contains a
substrate linker LSGRSDNH cleavable by the tumor-associated
serine proteases matriptase (MT-SP1) and urokinase plasminogen
activator (uPA) and by the cysteine protease legumain [10]. To
evaluate the kinetics of Pb-Tx activation in the tumor microenvi-
ronment of living animals, we previously used optical in vivo im-
aging with Pb-Tx constructs directly labeled with Alexa750, and
demonstrated that the Probody therapeutic could be detected
bound to tumors in a protease-dependent manner. However, this
direct imaging technique has several limitations, including passive
accumulation of the labeled Probody therapeutic in the highly
vascularized tumor compartment due to the enhanced perme-
ability and retention (EPR) effect, which can lead to high, non-
speciﬁc background in the images. To address this limitation, we
have developed an indirect approach that involves imaging using a
labeled EGFR antibody, cetuximab, and competing for binding ofthis agent in vivo using a non-labeled Pb-Tx. In this way, speciﬁc,
receptor-mediated binding of the activated Pb-Tx can be distin-
guished from non-speciﬁc EPR. Moreover, in contrast to conven-
tional in vivo imaging, which requires direct labeling of several
compounds, our competitive target binding approach uses only a
single labeled agent, the EGFR antibody, which minimizes vari-
ability that is often associated with labeling of multiple testing
agents, and eliminates potential effects of labeling on compound
distribution, circulation half-life or binding.
To evaluate this new approach, we used the H292 EGFR-
dependent lung cancer xenograft model, due to its high expres-
sion of EGFR [11] and our prior experience with in vivo imaging
using directly labeled Pb-Tx in this model [10]. In that previous
study, signiﬁcant Probody therapeutic activation and binding in the
tumormicroenvironment was detected 48 h after administration of
labeled Pb-Tx. Therefore, in the current study, 48 h pre-treatment of
tumor-bearing mice with non-labeled Pb-Tx was used, followed by
in vivo imaging with the parental anti-EGFR antibody (Ab) conju-
gated with the near-infrared (NIR) ﬂuorescent dye Alexa Fluor® 750
(Ab-AF750) (Fig. 2a). The H292 xenograft mouse model was
developed by subcutaneous inoculation of 5  106 NCI-H292 cells
suspended 1:1 (v/v) with Matrigel. After tumors reached a volume
of 250e500 mm3, animals were pre-treated with 10 mg/kg of un-
labeled Pb-Tx. In addition, control groups of animals were pre-
treated either with PBS or 10 mg/kg of unlabeled parental anti-
EGFR antibody (Ab) to demonstrate the maximal detectable dy-
namic range of antigen-dependent accumulation of the labeled
antibody. To evaluate the antigen-dependent accumulation of
Probody therapeutics, all mice were administered Ab-AF750 48 h
after pretreatment with cold Probody therapeutics, thus enabling
the detection of non-occupied EGFR. Spectral ﬂuorescence images
of the mice obtained with an IVIS Spectrum/CT imaging system at
48 h and 72 h after administration of Ab-AF750 demonstrated a
lower level of tumor-associated NIR ﬂuorescence in the groups
pretreated with anti-EGFR Ab or Pb-Tx than in mice pre-treated
with PBS (Fig. 2b). Tumor-to-background ratios (TBR) were calcu-
lated based on the average radiant efﬁciency detected at the tumor
site and a speciﬁed non-tumor area. A signiﬁcant decrease of TBR
was demonstrated for mice pre-treated with Probody therapeutics
when compared to PBS pre-treated animals at both the 48 h and
72 h time points (Fig. 2c). These results demonstrate that both anti-
EGFR antibody and Probody therapeutics can effectively compete
for binding to tumor EGFR with the labeled anti-EGFR antibody
in vivo, as detected by optical imaging. Previously, we demonstrated
that Pb-Tx does not detectably bind EGFR in the absence of protease
activity in vitro, and that the binding of directly labeled Pb-Tx to
EGFR in vivo in this tumor model is dependent of the presence of
the protease substrate [10]. Taken together, these data suggest that
our indirect, in vivo competition binding method can image pro-
tease activity associated with H292 tumors in vivo.
3.2. Matriptase activity is required for activation of Pb-Tx in H292
xenograft model
To further conﬁrm that binding of Pb-Tx to EGFR in H292 tumors
is dependent on protease activity, we characterized the protease
proﬁle of H292 xenograft tumors. Because Pb-Tx was designed to
be activated by matriptase, we used an active-siteespeciﬁc, re-
combinant human antibody for matriptase, called A11, which binds
only to the active form of matriptase and inhibits its activity [7,12].
A11 was labeled with AlexaFluor 488 (AF7488) and immunoﬂuo-
rescence staining was performed on formalin-ﬁxed parafﬁn-
embedded (FFPE) H292 xenograft tumor sections. As shown in
Fig. 3a, active matriptase is localized to H292 cancer cells, with a
characteristic membranous pattern of staining (Fig. 3a). The
Fig. 2. In vivo imaging of Pb-Tx EFGR binding in an H292 xenograft model. (A) Schematic of the in vivo optical imaging method. Imaging was performed at 48 and 72 h following
injection of cetuximab-AF750 into H292 tumor-bearing mice pretreated with PBS or a 10 mg/kg blocking dose of cetuximab or Pb-Tx. (B) Representative images of mice (n ¼ 3) from
each treatment group at 48 h. (C) Comparison of mean tumor-to-background ratios (TBR) based on average radiant efﬁciency values from cetuximab-AF750 in each group. Each bar
represents mean TBR ± SEM; n ¼ 3 for each group. *P < 0.05, **P < 0.01.
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using NIR optical imaging. A11 IgG labeledwith the NIR ﬂuorophore
AlexaFluor 750 (A11-AF750) was administered to mice bearing
H292 xenografts tumors and imaged at excitation and emission
wavelengths of 745 nm and 800 nm, respectively. Signiﬁcant
accumulation of labeled A11 probe as compared to non-binding
control anti-human CD20 antibody (Rituximab, Ritux-AF-750)
was detected at the tumor site (Fig. 3b), indicating the presence
of active matriptase in H292 xenografts in vivo. To test whether
matriptase activity is necessary for Pb-Tx binding, we pre-treated
H292 xenograft-bearing mice with 15 mg/kg of either unlabeled
A11 to inhibit matriptase activity or a control antibody (Rituximab)
and then performed NIR in vivo imaging with 10 mg/kg of Pb-Tx
directly labeled with AF-750 (Pb-Tx-AF750) after 24 h, 48 h and
72 h (Fig. 3c). Pb-Tx accumulation in tumors and TBR of average
radiant efﬁciency were calculated for each time point. Notably, a
signiﬁcant reduction of tumor-associated NIR ﬂuorescence was
detected in tumor-bearing mice pretreated with matriptase
inhibitory antibody as compared to mice pre-treated with non-binding antibody control (Fig. 3d and e). This data provides
further evidence that matriptase-dependent activation of Pb-Tx
results in accumulation of Pb-Tx in H292 xenograft tumors.
4. Conclusions
In summary, these results support that in vivo imaging with
Probody therapeutics can be a powerful tool for detection of pro-
tease activity in vivo. Furthermore, the novel in vivo competition
binding method presented in this work demonstrates the potential
for detection of protease activity in vivo without the limitations of
methods that use directly labeled Probody therapeutics. The
dependence of Pb-Tx tumor accumulation on protease activity was
conﬁrmed by reduced tumor target binding of Pb-Tx in the pres-
ence of a speciﬁc protease inhibitor. This conclusion is further
supported by previously published data that demonstrated that Pb-
Tx binding depends on the presence of the protease substrate in the
Probody therapeutic construct.
It should be noted that the ability to obtain data on protease
Fig. 3. Imaging of protease activity in an H292 xenograft model. (A) Immunoﬂuorescence staining of matriptase activity using A11 active site-speciﬁc antibody in H292 xenograft
tumor sections. A11 antibody staining is in green and nuclei are stained with DAPI (blue). Scale bar, 100 mm. (B) NIR optical imaging of A11-AF750 antibody accumulation in an H292
xenograft tumor model (right mouse). Rituximab-AF750 antibody was used as a negative, non-binding antibody control (left mouse). The images shown are representative of n ¼ 3
mice/xenograft. (C) Schematic of the in vivo optical imaging study of Pb-Tx binding to tumor EGFR in the presence of matriptase inhibitor. Imaging was performed 24 h, 48 h and
72 h after injection of 10 mg/kg Pb-Tx-AF750 into H292 tumor-bearing mice pretreated with 15 mg/kg of either unlabeled A11 or a control antibody (Rituximab). (D) Representative
images of mice (n ¼ 3) from each treatment group at 48 h. (E) NIR optical imaging of Pb-Tx in H292 xenograft tumor bearing mice pre-treated with rituximab or the inhibitory
matriptase matriptase antibody A11, followed by administration of labeled Pb-Tx-AF750. The TBR determined for both groups of mice (n ¼ 3) demonstrate decrease of NIR
ﬂuorescence in tumors of mice pretreated with matriptase inhibitor A11. *P < 0.05, **P < 0.01.
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mal is an important advantage of the in vivo imaging approach,
enabling generation of more data points from fewer animals. In
addition, the non-invasive assessment of protease activity in vivo
minimizes the possibility of data being confounded by changes in
protease activity from tissue/cellular damage during tissue pro-
cessing. Taken together, in vivo imaging with Probody therapeutics
represents a valuable approach for monitoring protease activities in
living animals, and enables evaluation of their role in development
and progression of diseases, such as cancer. This informationwould
be very useful for the validation of proteases as therapeutic targets
and development of potent protease activatable drugs, such as
Probody therapeutics.Conﬂict of interest
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